ImageneBio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
ImageneBio, Inc. (IMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.97% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-10
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-09-30 was 4.13%, a 12.68% decline year-over-year.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-06-30 was 4.43%, a 13.88% increase year-over-year.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.17%, a 6.38% increase year-over-year.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-09-30 was 4.73%, a 63.67% increase year-over-year.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.97%, a 0.51% increase from fiscal 2024.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.95%, a 1.25% decline from fiscal 2023.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.00%, a 65.29% increase from fiscal 2022.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.42%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | 3.97% 10-K · filed 2026-03-10 | |||||
| 2025-09-30 | 4.03% 10-Q · filed 2025-11-12 | |||||
| 2024-12-31 | 3.95% 10-K · filed 2026-03-10 | 4.18% 10-K · filed 2025-03-06 | ||||
| 2024-09-30 | 4.13% 10-Q · filed 2024-11-07 | 3.95% 10-Q · filed 2025-11-12 | 4.18% 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | 4.43% 10-Q · filed 2025-07-24 | 4.19% 10-Q · filed 2025-07-24 | ||||
| 2024-03-31 | 4.17% 10-Q · filed 2025-05-08 | |||||
| 2023-12-31 | 4.00% 10-K · filed 2025-03-06 | |||||
| 2023-09-30 | 4.73% 10-Q · filed 2024-11-07 | 3.91% 10-Q · filed 2024-11-07 | ||||
| 2023-06-30 | 3.89% 10-Q · filed 2024-08-08 | 3.91% 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | 3.92% 10-Q · filed 2024-05-13 | |||||
| 2022-12-31 | 2.42% 10-K · filed 2024-03-12 | |||||
| 2022-09-30 | 2.89% 10-Q · filed 2023-11-09 | 2.36% 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | 1.67% 10-Q · filed 2023-08-10 | 2.23% 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | 1.67% 10-Q · filed 2023-05-15 | |||||
| 2021-06-30 | 0.73% 10-Q · filed 2021-08-12 | |||||
| 2021-03-31 | 0.70% 10-Q · filed 2022-05-12 | |||||
| 2020-06-30 | 0.47% 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |